PharmAthene, Inc. (AMEX: PIP)

PharmAthene, Inc. (AMEX: PIP) is focused on addressing the critical needs of the United States and its allies through the development and commercialization of medical countermeasures against biological and chemical weapons. Currently, the company’s lead product development programs include: SparVax, an anthrax vaccine; a third generation rPA anthrax vaccine; Valortim, an antibody designed to prevent and treat anthrax infection; Protexia, a bioscavenger; and RypVax, a dual antigen vaccine for plague. For further information, visit the Company’s web site at www.pharmathene.com.